A physician sits in a reading room in Cleveland. Before she touches a single chart, an AI agent has already triaged her queue, flagged a coronary risk from an incidental scan, and routed three patients to telemedicine. That is not a pilot. That is production in 2026.
This week in healthcare funding did not produce a single blockbuster clinical AI IPO or a moonshot drug delivery company. What it produced was something quieter and more important: five checks written to companies solving the operational gut-punches of healthcare. Revenue cycle waste. Agentic workflow gaps. Medicare payment infrastructure. Remote chronic care delivery. Pharmacy fill-rate failures.
$295 million total. Five deals. One very clear thesis.
